Company Overview of Bio-Cancer Treatment International Ltd.
Bio-Cancer Treatment International, Ltd. operates as a biotech company in Hong Kong. It develops BCT-100, an anti-cancer drug candidate, which is a recombinant human enzyme for the treatment of cancers that are dependent on arginine for growth. The company also develops chemical synthetic technology to produce polyethylene glycol; and mSPA-PEG, a bio-polymer used in the production of BCT-100 and other protein therapeutics. It has strategic partnerships with Morningside Asia and Kinexum. The company was founded in 2001 and is based in Shatin, Hong Kong.
Hong Kong Science Park
2 Science Park West Avenue
Room 511-513, 5/F
Founded in 2001
852 2521 1566
852 2521 1560
Key Executives for Bio-Cancer Treatment International Ltd.
Bio-Cancer Treatment International Ltd. Key Developments
Similar Private Companies By Industry
|Antiviral Technologies, Inc.||Asia|
|Bio-Cancer Treatment International Ltd.||Asia|
|Bio-Works Company Limited||Asia|
|China Gene, Ltd. (Hong Kong)||Asia|
|DiagCor Bioscience Incorporation Limited||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Bio-Cancer Treatment International Ltd., please visit www.bio-cancer.org. Company data is provided by Capital IQ. Please use this form to report any data issues.